For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 90,300 | |||
| General and administrative | 22,491 | |||
| Total operating expenses | 112,791 | |||
| Total operating loss | -112,791 | |||
| Interest income, including amortization and accretion income | 6,631 | |||
| Other income (expense) | 77 | |||
| Total other income | 6,708 | |||
| Loss before income taxes | -106,083 | |||
| Income tax provision, net | 108 | |||
| Net loss | -106,191 | |||
| Unrealized loss on marketable securities | -179 | |||
| Currency translation adjustment | -186 | |||
| Total other comprehensive loss | -365 | |||
| Total comprehensive loss | -106,556 | |||
| Basic EPS | -1.76 | |||
| Diluted EPS | -1.76 | |||
| Basic Average Shares | 60,337,608 | |||
| Diluted Average Shares | 60,337,608 | |||
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)